Cetirizine
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
- Cetirizine
- Pharmacist Assessment Report
- Cetirizine: H1 receptor antagonist (antihistamine) → nasal cavity disease
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Cetirizine: H1 receptor antagonist (antihistamine) → nasal cavity disease
One-Sentence Summary
Cetirizine is an H1-receptor antagonist antihistamine marketed in India in many single-ingredient products. The TxGNN model predicts it may be effective for nasal cavity disease, a broad and non-specific term. Currently no clinical trials and 5 publications (mostly reviews and unrelated preclinical work) are linked to this prediction, so the evidence is limited.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | nasal cavity disease |
| TxGNN Prediction Score | 0.9977 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Cetirizine blocks histamine H1 receptors, which are found on nerve endings, smooth muscle and glandular cells. Detailed mechanism-of-action data were not available in the data compiled for this report. Published reviews also describe additional anti-allergic effects of H1 antagonists, such as reduced eosinophil chemotaxis and mediator release.
These properties are relevant to allergic and inflammatory conditions of the nose. However, “nasal cavity disease” is a very broad term. The best-supported part of it, allergic rhinitis, is already covered by existing use of the drug. Any new value would therefore have to come from other inflammatory nasal or sinus conditions, which the prediction does not specify.
Because no cited study directly examines cetirizine in a defined nasal cavity disease beyond what is already known, the evidence level is set at L5 (model prediction with no direct study).
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11291777 | 2000 | Review | Allergy | H1-receptor antagonists act mainly by blocking histamine receptors, but may also have additional anti-allergic effects in allergic rhinitis |
| 37970776 | 2023 | Review | Vestnik otorinolaringologii | Treatment of nose and paranasal sinus inflammation should follow the underlying pathogenesis, aiming to reduce swelling and mucus |
| 35818943 | 2022 | Review | Vestnik otorinolaringologii | Modern H1 antihistamines in patients with allergic rhinitis who also have acute respiratory infections |
| 36116201 | 2022 | Preclinical (mouse, unrelated intervention) | Phytomedicine | Herbal capsule studied in a mouse model of allergic rhinitis; not about cetirizine |
| 9301130 | 1997 | Preclinical (different drug) | Arerugi | Betotastine tested in experimental allergic rhinitis; cetirizine used as a comparator that dose-dependently reduced the response |
India Market Information
The data list at least 20 valid single-ingredient licences, and the list may be partial. No approved-indication text is recorded for these licences. Main examples:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 12883 | Acrecet 10mg Tablet | Strip of 10 tablets | Not recorded |
| 205627 | Stencold Syrup | Bottle of 30 ml syrup | Not recorded |
| 116914 | Kolcare Tablet | Strip of 10 tablets | Not recorded |
| 51370 | Cetrish 10mg Tablet | Strip of 10 tablets | Not recorded |
| 52831 | Cetnir Syrup | Bottle of 60 ml syrup | Not recorded |
Safety Considerations
- Drug Interactions: 570 interactions were recorded. Those listed as moderate include bupropion, dronabinol, loperamide, metoclopramide, morphine, nabilone, opium, sibutramine, difenoxin and diphenoxylate. Several others (e.g. calcitriol, vitamin A, phentermine, pantoprazole, glimepiride) have an unknown severity level.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but “nasal cavity disease” is too broad to act on. No clinical trials exist, and the cited literature consists of reviews and unrelated preclinical studies. The best-supported use, allergic rhinitis, is already covered.
To proceed, the following is needed:
- A specific nasal or sinus condition, beyond allergic rhinitis, to test
- Clinical studies that directly examine cetirizine in that condition
- Package insert warnings and contraindications from the India label
- Detailed mechanism-of-action data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.